These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 36652274)
61. A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy. Nguyen H; Ahmed K; Luo W; Flint J; Giles I Semin Arthritis Rheum; 2021 Dec; 51(6):1205-1217. PubMed ID: 34689007 [TBL] [Abstract][Full Text] [Related]
62. Characteristics of biological therapy in pediatric patients with Crohn's disease. Tarnok A; Kiss Z; Kadenczki O; Veres G Expert Opin Biol Ther; 2019 Mar; 19(3):181-196. PubMed ID: 30601083 [TBL] [Abstract][Full Text] [Related]
63. Safety and Efficacy of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines During Lactation. Shook LL; Edlow AG Obstet Gynecol; 2023 Mar; 141(3):483-491. PubMed ID: 36649326 [TBL] [Abstract][Full Text] [Related]
64. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients. Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155 [TBL] [Abstract][Full Text] [Related]
65. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Borren NZ; Ananthakrishnan AN Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024 [TBL] [Abstract][Full Text] [Related]
66. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576 [No Abstract] [Full Text] [Related]
67. Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohort. Mitrova K; Cerna K; Zdychyncova K; Pipek B; Svikova J; Minarikova P; Adamcova M; David J; Lukas M; Duricova D Eur J Pediatr; 2024 Jul; ():. PubMed ID: 39023645 [TBL] [Abstract][Full Text] [Related]
68. Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine--a randomized trial. Ali A; Kazi AM; Cortese MM; Fleming JA; Moon S; Parashar UD; Jiang B; McNeal MM; Steele D; Bhutta Z; Zaidi AK PLoS One; 2015; 10(6):e0127622. PubMed ID: 26035743 [TBL] [Abstract][Full Text] [Related]
69. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T; Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149 [TBL] [Abstract][Full Text] [Related]
70. Live attenuated vaccines under immunosuppressive agents or biological agents: survey and clinical data from Japan. Kamei K; Miyairi I; Shoji K; Arai K; Kawai T; Ogura M; Ishikura K; Sako M; Nakamura H Eur J Pediatr; 2021 Jun; 180(6):1847-1854. PubMed ID: 33523302 [TBL] [Abstract][Full Text] [Related]
71. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Wieringa JW; Driessen GJ; Van Der Woude CJ Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):811-818. PubMed ID: 29972674 [TBL] [Abstract][Full Text] [Related]
72. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964 [TBL] [Abstract][Full Text] [Related]
73. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines. Benchimol EI; Tse F; Carroll MW; deBruyn JC; McNeil SA; Pham-Huy A; Seow CH; Barrett LL; Bessissow T; Carman N; Melmed GY; Vanderkooi OG; Marshall JK; Jones JL Gastroenterology; 2021 Aug; 161(2):669-680.e0. PubMed ID: 33617891 [TBL] [Abstract][Full Text] [Related]
74. Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis. Gubatan J; Nielsen OH; Levitte S; Juhl CB; Maxwell C; Streett SE; Habtezion A Am J Gastroenterol; 2021 Feb; 116(2):243-253. PubMed ID: 33110017 [TBL] [Abstract][Full Text] [Related]
75. Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study. Bendaoud S; Nahon S; Beaugerie L; Gornet JM; Wils P; Amiot A; Peyrin-Biroulet L; Abitbol V; Hébuterne X; Altwegg R; Rosa I; Amil M; Heluwaert F; Plastaras L; Stefanescu C; Quentin V; Antoni M; Bideau K; Boualit M; Cuillerier E; Locher C; Skinazi F; Boureille A; Buisson A; Simon M Dig Liver Dis; 2024 Jul; ():. PubMed ID: 38981787 [TBL] [Abstract][Full Text] [Related]
76. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W Am J Gastroenterol; 2022 Jul; 117(7):1106-1117. PubMed ID: 35435862 [TBL] [Abstract][Full Text] [Related]
77. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Lin S; Kennedy NA; Saifuddin A; Sandoval DM; Reynolds CJ; Seoane RC; Kottoor SH; Pieper FP; Lin KM; Butler DK; Chanchlani N; Nice R; Chee D; Bewshea C; Janjua M; McDonald TJ; Sebastian S; Alexander JL; Constable L; Lee JC; Murray CD; Hart AL; Irving PM; Jones GR; Kok KB; Lamb CA; Lees CW; Altmann DM; Boyton RJ; Goodhand JR; Powell N; Ahmad T; Nat Commun; 2022 Mar; 13(1):1379. PubMed ID: 35296643 [TBL] [Abstract][Full Text] [Related]
78. State of the art: Could nursing mothers be vaccinated with attenuated live virus vaccine? Alain S; Dommergues MA; Jacquard AC; Caulin E; Launay O Vaccine; 2012 Jul; 30(33):4921-6. PubMed ID: 22659446 [TBL] [Abstract][Full Text] [Related]
79. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602 [TBL] [Abstract][Full Text] [Related]
80. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Wils P; Seksik P; Stefanescu C; Nancey S; Allez M; Pineton de Chambrun G; Altwegg R; Gilletta C; Vuitton L; Viennot S; Serrero M; Fumery M; Savoye G; Collins M; Goutorbe F; Brixi H; Bouguen G; Tavernier N; Boualit M; Amiot A; Abitbol V; Laharie D; Pariente B; Aliment Pharmacol Ther; 2021 Feb; 53(4):460-470. PubMed ID: 33345331 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]